Rakuten Investment Management Inc. Invests $592,000 in Hologic, Inc. $HOLX

Rakuten Investment Management Inc. purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,772 shares of the medical equipment provider’s stock, valued at approximately $592,000.

Several other hedge funds have also added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. K.J. Harrison & Partners Inc bought a new position in Hologic in the second quarter valued at approximately $1,987,000. Aberdeen Group plc boosted its holdings in shares of Hologic by 2.8% in the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock valued at $15,964,000 after buying an additional 6,589 shares during the period. Nordea Investment Management AB increased its position in shares of Hologic by 7.2% during the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock worth $168,674,000 after acquiring an additional 174,828 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Hologic during the third quarter worth $4,170,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HOLX shares. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $70.00 to $78.00 in a research note on Thursday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 price objective on shares of Hologic in a report on Wednesday, October 22nd. Morgan Stanley lifted their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Stephens downgraded Hologic from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat, Hologic has an average rating of “Hold” and an average target price of $79.31.

Hologic Stock Performance

NASDAQ HOLX opened at $75.05 on Friday. The firm has a market capitalization of $16.73 billion, a P/E ratio of 30.26, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. The firm’s fifty day moving average price is $74.80 and its two-hundred day moving average price is $70.56. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.34.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.01 EPS. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.